The P-I clinical trial evaluates the safety, efficacy & tolerability of FHD-286 (2.5/5.0/7.5/10.0mg qd or 10.0/15.0/17.5/20.0/22.5mg qw) in patients (n=73) with metastatic uveal melanoma (mUM) that have been treated with a median of two prior therapies across 9 different cohorts
Of the 47 target lesion evaluable patients, 1 depicted a durable response & remained on treatment for ≥16mos., 9 showed a stable disease & 8 had tumor reductions in target lesions. The clinical study was further supported by the reduction in ctDNA
FHD-286 is a selective, allosteric, small-molecule enzymatic inhibitor of BRG1 (SMARCA4) & BRM (SMARCA2). Additionally, Foghorn expects to initiate a P-I clinical trial evaluating FHD-286 + decitabine/cytarabine in r/r AML patients by Q3’23
Ref: Foghorn | Image: Foghorn
Related News:- Lilly Collaborates with Foghorn to Develop Novel Oncology Therapies for the Treatment of Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
